Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 941-949

  Ochs, Judith S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

EGFR; Gefitinib; IRESSA; Radiation; Tyrosine kinase inhibitor

Indexed keywords

AMINO ACIDS; CELLS; ENZYMES; IONIZING RADIATION; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY; TUMORS;

CYTOTOXICITY; RADIOSENSITIVITY;

ONCOLOGY;

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB;

ACNE; ADD ON THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; ENZYME ACTIVITY; ENZYME ANALYSIS; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; HYPERCALCEMIA; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RADIOSENSITIVITY; RASH; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MODEL; XENOGRAFT;

EID: 1242293093     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.094     Document Type: Conference Paper

References (51)

1. Ethier S.P., Lawrence T.S. Epidermal growth factor receptor signaling and response of cancer cells to ionizing radiation. J Natl Cancer Inst. 93:2001;890-891.
2. Harari P.M., Huang S.-M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol. 11:2001;281-289.
3. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60:(Suppl. 1):2000;15-23.
4. Sartor C.I. Biological modifiers as potential radiosensitizers Targeting the epidermal growth factor receptor family . Semin Oncol. 27:(Suppl. 11):2000;15-20.
5. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:2001;127-137.
6. Prenzel N., Fischer O.M., Streit S., et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 8:2001;11-31.
7. Moghal N., Sternberg P.W. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol. 11:1999;190-196.
8. Hackel P.O., Zwick E., Prenzel N., et al. Epidermal growth factor receptors Critical mediators of multiple receptor pathways . Curr Opin Cell Biol. 11:1999;184-189.
9. Barker F.G. II, Simmons M.L., Chang S.M., et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 51:2001;410-418.
10. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5:1999;2884-2890.
11. Schmidt M., Lichtner R.B. EGF receptor targeting in therapy-resistant human tumors. Drug Resist Update. 5:2002;11-18.
12. Raben D., Helfrich B.A., Chan D., et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 29:(Suppl. 4):2002;37-46.
13. Harari P.M., Huang S.-M. Modulation of molecular targets to enhance radiation. Clin Cancer Res. 6:2000;323-325.
14. Milas L., Akimoto T., Hunter N.R., et al. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys. 52:2002;514-521.
15. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer Relationship to radiation resistance and signal transduction . Clin Cancer Res. 8:2002;885-892.
16. Dent P., Reardon D.B., Park J.S., et al. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 10:1999;2493-2506.
17. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 15:1997;1191-1197.
18. Carter S., Auer K.L., Reardon D.B., et al. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene. 16:1998;2787-2796.
19. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929.
20. Contessa J.N., Reardon D.B., Todd D., et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res. 5:1999;405-411.
21. Pedersen M.W., Meltorn M., Damstrup L., et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 12:2001;745-760.
22. Lammering G, Hewit TH, Contessa JN, et al. EGFR and its mutant EGFRvIII as modulators of tumor cell radiosensitivity (Abstract). Proc Am Soc Ther Radiol Oncol 2002;103.
23. Harari P.M., Huang S.-M. Head and neck cancer as a clinical model for molecular targeting of therapy Combining EGFR blockade with radiation . Int J Radiat Oncol Biol Phys. 49:2001;427-433.
24. Huang S.-M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis . Clin Cancer Res. 6:2000;2166-2174.
25. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063.
26. Wakeling A.E., Guy S.P., Woodburn J.R., et al. ZD1839 (Iressa) An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy . Cancer Res. 62:2002;5749-5754.
27. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients Histopathologic and molecular consequences of receptor inhibition . J Clin Oncol. 20:2002;110-124.
28. Huang S.-M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62:2002;4300-4306.
29. Hirata A., Ogawa S., Kometani T., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2002;2554-2560.
30. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 8:2002;3250-3258.
31. Ambrad AA, Stea B, Martinez J, et al. ZD1839 ('Iressa') an EGFR tyrosine kinase inhibitor radiosensitizes glioblastoma multiforme by inhibition of a cell survival pathway (Abstract). Proc Am Soc Ther Radiol Oncol 2002;95.
32. Williams K.J., Telfer B.A., Stratford I.J., et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 86:2002;1157-1161.
33. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:2002;4292-4302.
34. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors Results of a phase I trial . J Clin Oncol. 20:2002;2240-2250.
35. Herbst R.S., Maddox A.-M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors Results of a phase I trial . J Clin Oncol. 20:2002;3815-3825.
36. Herbst R.S., Kies M.S. ZD1839 (Iressa™) in non-small cell lung cancer. Oncologist. 7:(Suppl. 4):2002;9-15.
37. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246.
38. Kris M. A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Presented at: American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL.
39. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21(1):292a.
40. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 19:2001;3234-3243.
41. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 21:2003;1980-1987.
42. Herbst R.S., Hong W.K. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol. 29:(Suppl. 14):2002;18-30.
43. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002;21:293a.
44. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment The emerging role of IMC-C225 in the treatment of lung and head and neck cancers . Semin Oncol. 29:(Suppl. 4):2002;27-36.
45. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279.
46. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20(1):310a.
47. Oza A.M., Townsley C.A., Siu L.L., et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 22:2003;196.
48. Chinnaiyan P., Huang S.-M., Armstrong E., et al. Enhanced radiation response following HER1/EGFR blockade by erlotinib (Tarceva™, OSI-774) in human carcinoma cell lines. Proc Am Assoc Cancer Res. 44:2003;867.
49. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000;18(Suppl.):47s-53s.
50. Mauer A, Haraf D, Hoffman PC, et al. for the University of Chicago Phase II Network. A phase I study of OSI-774 in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:651.
51. Pfister D.G., Aliff T.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN) Preliminary evaluation of a new combined-modality paradigm . Proc Am Soc Clin Oncol. 22:2003;495.